Phenylpropanolamine is a sympathomimetic that was previously used in nasal decongestants and weight loss products, but has been withdrawn by the FDA due to safety risks and lack of efficacy. Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor.
- Mechanism
- Curator reviewed
Phenylpropanolamine acts directly on alpha- and, to a lesser degree, beta-adrenergic receptors in the mucosa of the respiratory tract. Stimulation of alpha-adrenergic receptors produces vasoconstriction, reduces tissue hyperemia, edema, and nasal congestion, and increases nasal airway patency. PPA indirectly stimulates beta-receptors, producing tachycardia and a positive inotropic effect.
- Primary indication
- For the treatment of nasal congestion, control of urinary incontinence, priapism and obesity.Curator reviewed · 14 structured indications
- Formula / weight
- C9H13NO · 151.209 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1990
- Also known as
- Norephedrine · Phenylpropanolamine polistirex
Resolves to
DLNKOYKMWOXYQA-UHFFFAOYSA-NSMILESCC(N)C(O)C1=CC=CC=C1What you can answer from here — as of August 31, 2026
Which drugs share a target with Phenylpropanolamine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account